New exploratory TOGETHER-PsO data from Lilly found broader immune and metabolic changes in people with psoriasis and obesity when Zepbound was added, showing up as early as week 12.
Recap by typeshit. Full story at Stock Titan.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Lilly closed at $1,169.60, and one widely followed narrative pegs fair value near $1,477, citing retatrutide's Phase 3 results against pricing pressure.
Pairing eloralintide with tirzepatide beat tirzepatide alone at 48 weeks, at 23.3% versus 14.8% weight loss. Up to about a quarter of people on the combo quit because of side effects.
Loading…